A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bortezomib (Primary) ; Tanespimycin (Primary)
Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions

03 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
04 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
27 Dec 2007 The expected completion date for this trial is now 1 Jul 2006.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com